Jean-Yves Blay.

David M. Hyman, M.D ., Igor Puzanov, M.D., Vivek Subbiah, M.D., Jason E. Faris, M.D., Ian Chau, M.D., Jean-Yves Blay, M.D., Ph.D.D., Ph.D., Noopur S. Raje, M.D., Eli L. Diamond, M.D., Antoine Hollebecque, M.D., Radj Gervais, M.D., Maria Elena Elez-Fernandez, M.D., Antoine Italiano, M.D., Ph.D., Ralf-Dieter Hofheinz, M.D., Manuel Hidalgo, M.D., Ph.D., Emily Chan, M.D., Ph.D., Martin Schuler, M.D., Susan Frances Lasserre, M.Sc., Martina Makrutzki, M.D., Florin Sirzen, M.D., Ph.D., Maria Luisa Veronese, M.D., Josep Tabernero, M.D., Ph.D.D., Ph.D.: Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations BRAF V600 mutations occur in approximately 50 percent of cutaneous melanomas and result in constitutive activation of downstream signaling through the mitogen-activated proteins kinase pathway.1,2 Vemurafenib , version 1.1,18 and an Eastern Cooperative Oncology Group performance-status score of 0 to 2 .

The interaction term was dropped when it was not really significant. We included chances ratios and 95 percent self-confidence intervals in the assessment of 28-day time mortality for each intervention, both overall and separately, in the presence and absence of the other intervention.13 Finally, we conducted analyses involving prespecified subgroups, as described in the Supplementary Appendix. For all analyses of secondary outcomes, we performed individual comparisons of the two groupings that received glutamine with the two groups that did not receive glutamine and both groups that received antioxidants with the two groups that did not receive antioxidants. Percentages and Counts are presented for categorical variables, medians and quartiles for skewed variables, and means, regular deviations, and ranges for various other continuous variables.